July 25 (Bloomberg) -- Bayer AG’s Xarelto blood-thinner didn’t raise the risk of bleeding for irregular-heartbeat patients in a Japanese study comparing the medicine with warfarin, the former standard of care, the Leverkusen, Germany-based company said today.
The results confirmed those of the global Rocket study, Bayer said. The German drug and chemicals maker said in April it requested Japanese approval for Xarelto for irregular-heartbeat patients.
To contact the reporter on this story: Naomi Kresge in Zurich at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com